Emergent BioSolutions | EBS - Sales Revenues


Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exact Sciences USD 878.38M 27.38M Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
Lexicon Pharmaceuticals USD 1.65M 520K Jun/2024
Lonza CHF 3.58B 63M Jun/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma USD 25K 5M Sep/2024